Skip to main content
. 2015 Jul 30;10:118. doi: 10.1186/s13018-015-0264-y

Table 1.

Biological agents, commercial stock solution concentrations, applied volumes, and final concentrations

BA Commercial stock solution concentration (mg/mL) Applied volumes (μL/mL) Final concentration (μL/mL)
Rituximab (RIT) 250 1 10
Adalimumab (ADA) 500 0.2 10
Abatacept (ABA) 40 1 10
Etanercept (ETA) 50 0.4 10
Infliximab (INF) 100 0.8 10

One well 3 mL in volume will allow the BA application